NCT04164199 2026-04-14
Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies
BeOne Medicines
Phase 3 Active not recruiting
Clinical Trials
7 trialsNCT07491159 2026-03-24
Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study
Tianjin Medical University Cancer Institute and Hospital
Phase 1/2 Active not recruiting
NCT06356597 2026-02-24
Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial
Shanghai Jiao Tong University School of Medicine
Phase 2 Active not recruiting
NCT05565417 2025-10-16
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas
Immunitas Therapeutics
Phase 1/2 Active not recruiting
NCT05177068 2025-10-02
Conversion Therapy of Fruquintinib in Combination With Sintilimab and SOX in Unresectable Gastric Cancer
Henan Cancer Hospital
Phase 2 Active not recruiting
NCT06199973 2025-07-17
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 3 Active not recruiting
NCT05661357 2024-04-17
HCCSC-C03
Zhongnan Hospital
Phase 4 Active not recruiting